The treatment of osteoporosis consists of lifestyle measures and pharmacologic therapy. Newer agents are knocking the door as they have shown decent results in trials. Abaloparatide It is an investigational synthetic analog of parathyroid hormone-related peptide (PTHrP) that binds more selectively than parathyroid hormone 1-34 (teriparatide) to the PTH1 receptor, conferring a more transient response favoring bone formation and minimizing bone resorption and hypercalcemia. In a phase III trial , nearly 2500 postmenopausal women with osteoporosis were randomly assigned to abaloparatide, placebo, or open-label teriparatide.
Compared with placebo, new radiographic vertebral fractures occurred less frequently in the abaloparatide and teriparatide groups. The incidence of hypercalcemia was lower with abaloparatide than teriparatide. Sclerostin inhibitors Sclerostin is produced by osteocytes…
